InnomarLive 2023: Emerging trends in the oncology ecosystem

Conference Series:

Join us to learn and engage in conversation around the impact of emerging changes in the oncology landscape and the effect on drug approvals, reimbursement, and patient care.

Conference highlights:

• How stakeholders are addressing the increasing volume of new oncology treatments 
• The challenges faced by payers in the evaluation of new therapies
• Delivering quality care in a resource-constrained environment: The oncologist perspective
• Seeking diagnosis and treatment: The patient perspective
• The promise of new cancer therapies, balanced with the need for drug plan sustainability 
• The potential role of RWE in the evaluation of new oncology drugs

You should attend if you work in:

• Market Access / Reimbursement 
• Regulatory Affairs 
• Marketing / Market Research 
• Stakeholder Relations / Government Affairs 
• New Product Launches / Drug Commercialization 
• Drug Plan Management - Public and Private Payers 

Guest speakers include:

• Melissa Hunt, Director, Bureau of Metabolism, Oncology and Reproductive Sciences, Pharmaceutical Drugs Directorate, Health Canada
• Brent Fraser, Vice President, Pharmaceutical Reviews, CADTH
• Sylvie Bouchard, Director, Drug Evaluation and Technologies for Reimbursement Directorate, INESSS
• Daniel Sperber, Senior Economist, pan-Canadian Pharmaceutical Alliance (pCPA)
• Daria O’Reilly, Lead Health Economist, Pharmacy Consulting Health Benefits and Payment Solutions, TELUS Health
• Durhane Wong-Rieger, President and CEO, CORD
• Carlene Todd, Vice President, Access, Hoffmann-La Roche Limited
• Dr. Gerald Batist, Director, Dept. of Oncology, Sir Mortimer B. Davis-Jewish General Hospital;
  Director, McGill University Centre for Translational Research in Cancer Professor, Department of Oncology, McGill University
• Claire Edmonds, Registered Psychotherapist, affiliated with Wellspring
• Shirley Chen, Medication Reimbursement Specialist, Princess Margaret Cancer Centre
• Dale Hanna, Director, Cell and Gene Therapy Solutions, AmerisourceBergen
• Nicole Mittmann, Vice-President, Scientific Evidence, Methodologies, and Resources, CADTH
• Sandra Anderson, SVP International Commercialization, Amerisource Bergen

Pricing (per attendee) – Full day conference:

$750 – 1 attendee
$700 – 2-5 attendees
$650 – 5 – 7 attendees
$600 – 8+ attendees

Reserve your spot and register today!

To register, please click the email address below and provide; organization name, attendee names and titles, and payment preference (credit card or invoice).
InnomarLive@innomar-strategies.com

Please note, this is an English only event with no virtual option.

*Please note: You may use a credit card or choose to be invoiced by Innomar Strategies.